ESG Report17 September 2026Arovella Therapeutics LimitedABN 35 090 987 250www.arovella.comENVIRONMENTALSOCIAL GOVERNANCE Arovella Therapeutics | ESG report Page 2 Corporate One, 84 Hotham Street, Preston, VIC 3072 Australia Telephone: + 61 3 9863 6472 info@arovella.com | www.arovella.com ...
2026 ESG Report
Filed with ASX · · 11 pages · English
On 6ix: 6ix.com/news/2026-esg-report
Release
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Notification of 2026 AGM Date
- Clinical manufacturing batch released, first site activated
- Corporate Governance Statement
- Appendix 4G
- Appendix 4E and Annual Report
Later from Arovella Therapeutics
- The path to first patient dosing
- Notice of Annual General Meeting/Proxy Form
- Cell and Gene Innovation Spotlight Presentation
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics